CancerNCT07708935
Real-World Study of Young Patients With Solid Tumors in China
An observational study of Cancer, run by Fudan University at 1 site in China.
Trial summary
To evaluate organ preservation rates, fertility preservation, and long-term quality of life after treatment among young patients. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Cancer
- What is being tested?
- Ages 18-40
- How many people
- 12,000 participants
- Where
- 1 siteChina
- Study dates
- 31 Jul 2026to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Young Patients with Malignant Solid Tumors
Who may be able to join
- Confirmed Diagnosis: Patients with malignant solid tumors confirmed by histopathological or cytological examination. The primary tumor types of interest include, but are not limited to, breast cancer, malignant melanoma, and multiple primary tumors.
- Age and Cohort Definitions:
- 2.1. Young Cohort (Core Population): Patients aged ≤40 years at the time of initial diagnosis of a malignant tumor.
- 2.2. Older Control Cohort: Patients aged >40 years at the time of initial diagnosis of a malignant tumor. Patients will be selected proportionally according to the incidence of each tumor type and propensity score matching principles.
- Eligible Time Window: The initial diagnosis or receipt of antitumor treatment at the participating center must have occurred between January 1, 2010, and May 31, 2026.
- Treatment History: Patients must have received at least one standard antitumor treatment at a participating study center, including but not limited to curative or palliative surgery, neoadjuvant or adjuvant systemic therapy, and first-line or later-line chemotherapy, targeted therapy, or immunotherapy for advanced disease.
Show all 9Show fewer
- Availability of Multimodal Data:
- 5.1. Relatively complete clinical records must be available, including baseline demographic characteristics, medical records, treatment regimens, and follow-up records.
- 5.2. Baseline imaging data must be available, such as CT, MRI, or PET-CT scans. 5.3. Pathological tissue samples, such as formalin-fixed, paraffin-embedded (FFPE) blocks or unstained slides, must be available to support subsequent digital pathology and radiomic feature extraction.
Who cannot join
- Uncertain Diagnosis: Patients with an inconclusive histopathological or cytological diagnosis, or without clear documentation of tumor stage according to the TNM staging system.
- Severe Missingness of Core Data: Patients with substantially incomplete clinical records, such as missing documentation of key treatment regimens, absence of any baseline imaging assessment, or no follow-up records whatsoever due to loss to follow-up.
- Potential Confounding From Multiple Primary Malignancies: Patients with a concurrent malignancy or a history of another malignancy within the previous 5 years, except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, or papillary thyroid carcinoma, to avoid confounding the analysis of survival outcomes, including overall survival (OS) and progression-free survival (PFS).
- Deemed Unsuitable by the Investigator: Patients considered by the investigator, based on clinical judgment, to have other conditions that make them unsuitable for inclusion in this study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Fudan University Shanghai Cancer Center
Shanghai
Juan Jin, PhD, 021-33988888, medjinjuan@126.com
About this study
Official title: A Multicenter Real-World Study on the Diagnosis, Treatment, and Long-Term Survival of Young Patients With Malignant Solid Tumors in China
To evaluate organ preservation rates, fertility preservation, and long-term quality of life after treatment among young patients.
Read the detailed description
This is a multicenter, retrospective, real-world study. The study will systematically collect data on treatment strategies and multimodal characteristics of young patients with malignant solid tumors in China who receive care in real-world clinical settings.
This is a non-interventional study conducted entirely on the basis of routine clinical decisions made by treating physicians, without interfering with any aspect of the patients' treatment. By analyzing the characteristics, multimodal omics data, and long-term survival outcomes of young patients receiving different treatment strategies, this study aims to provide real-world evidence to support the optimization of precision diagnosis and treatment for malignant tumors in young patients.
- Conditions
- Cancer
- Being tested
- Ages 18-40
- Keywords
- Young Patients with Malignant Solid Tumors
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ages 18-40Other
Young Cohort (Core Population): Patients aged ≤40 years at the time of initial diagnosis of a malignant tumor.
Older Control Cohort: Patients aged >40 years at the time of initial diagnosis of a malignant tumor, selected proportionally according to the incidence of each tumor type and propensity score matching principles.
| Study group | Role | What they receive |
|---|---|---|
| Young Patients with Malignant Solid Tumors | Young Patients with Malignant Solid Tumors Receives: Other: Ages 18-40 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of Special Needs and Quality of Life (QoL)
To evaluate organ preservation rates during treatment among young patients, including breast-conserving surgery, sphincter-preserving surgery, and limb-sparing surgery; fertility preservation; long-term quality of life after treatment; and the proportion of patients who return to society and/or work.
Measured: January 1, 2010 to December 31, 2027
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2026
- Study start31 Jul 2026 (estimated)
- Primary completion31 Jul 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by Fudan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 12,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fudan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hongxia Wang, Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07708935
- Sponsor's protocol ID
- RWS-DNK2026
- Status last verified
- Jul 2026
- First submitted
- 13 Jul 2026
- Last updated
- 16 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter Real-World Study on the Diagnosis, Treatment, and Long-Term Survival of Young Patients With Malignant Solid Tumors in China
- ClinicalTrials.gov ID
- NCT07708935
- Acronym / sponsor ID
- RWS-DNK2026
- Conditions
- Cancer
- Keywords
- Young Patients with Malignant Solid Tumors
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 12,000 participants (estimated)
- Lead sponsor
- Fudan UniversityUniversity, hospital or other
- Study start
- 31 Jul 2026 (estimated)
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 16 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate organ preservation rates, fertility preservation, and long-term quality of life after treatment among young patients.
Detailed description
This is a multicenter, retrospective, real-world study. The study will systematically collect data on treatment strategies and multimodal characteristics of young patients with malignant solid tumors in China who receive care in real-world clinical settings.
This is a non-interventional study conducted entirely on the basis of routine clinical decisions made by treating physicians, without interfering with any aspect of the patients' treatment. By analyzing the characteristics, multimodal omics data, and long-term survival outcomes of young patients receiving different treatment strategies, this study aims to provide real-world evidence to support the optimization of precision diagnosis and treatment for malignant tumors in young patients.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Young Patients with Malignant Solid Tumors | – | Other: Ages 18-40Young Patients with Malignant Solid Tumors |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Young Patients with Malignant Solid Tumors
Key inclusion criteria (9 listed)
- Confirmed Diagnosis: Patients with malignant solid tumors confirmed by histopathological or cytological examination. The primary tumor types of interest include, but are not limited to, breast cancer, malignant melanoma, and multiple primary tumors.
- Age and Cohort Definitions:
- 2.1. Young Cohort (Core Population): Patients aged ≤40 years at the time of initial diagnosis of a malignant tumor.
- 2.2. Older Control Cohort: Patients aged >40 years at the time of initial diagnosis of a malignant tumor. Patients will be selected proportionally according to the incidence of each tumor type and propensity score matching principles.
- Eligible Time Window: The initial diagnosis or receipt of antitumor treatment at the participating center must have occurred between January 1, 2010, and May 31, 2026.
Key exclusion criteria (4 listed)
- Uncertain Diagnosis: Patients with an inconclusive histopathological or cytological diagnosis, or without clear documentation of tumor stage according to the TNM staging system.
- Severe Missingness of Core Data: Patients with substantially incomplete clinical records, such as missing documentation of key treatment regimens, absence of any baseline imaging assessment, or no follow-up records whatsoever due to loss to follow-up.
- Potential Confounding From Multiple Primary Malignancies: Patients with a concurrent malignancy or a history of another malignancy within the previous 5 years, except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, or papillary thyroid carcinoma, to avoid confounding the analysis of survival outcomes, including overall survival (OS) and progression-free survival (PFS).
- Deemed Unsuitable by the Investigator: Patients considered by the investigator, based on clinical judgment, to have other conditions that make them unsuitable for inclusion in this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ages 18-40Young Cohort (Core Population): Patients aged ≤40 years at the time of initial diagnosis of a malignant tumor. Older Control Cohort: Patients aged >40 years at the time of initial diagnosis of a malignant tumor, selected proportionally according to the incidence of each tumor type and propensity score matching principles. | Other | Young Patients with Malignant Solid Tumors |
Primary outcome
Assessment of Special Needs and Quality of Life (QoL)
Time frame: January 1, 2010 to December 31, 2027
To evaluate organ preservation rates during treatment among young patients, including breast-conserving surgery, sphincter-preserving surgery, and limb-sparing surgery; fertility preservation; long-term quality of life after treatment; and the proportion of patients who return to society and/or work.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Fudan University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hongxia Wang (021-33988888, whx365@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of Special Needs and Quality of Life (QoL) (time frame: January 1, 2010 to December 31, 2027). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.